ArticleAmerican journal of translational research2025
Effects of ADRM1 on osteoblast differentiation and mineralization in osteoporosis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAdhesion regulating molecule-1 (ADRM1), a 26S proteasome adaptor protein, plays a crucial role in mediating the growth and differentiation of osteoclasts in osteoporosis (OP). However, its involvement in this osteoanabolic effect remains largely uninvestigated.
methods
resultsKnockdown of ADRM1 markedly promoted the growth of C3H10T1/2 cells while inhibiting apoptosis. Additionally, this intervention enhanced the expression of osteoblast differentiation markers and key proteins associated with the Wnt/β-catenin pathway. Notably, silencing ADRM1 promoted osteoblast mineralization and differentiation, as evidenced by increased Alizarin red staining and alkaline phosphatase staining. Conversely, MC3T3-E1 cells overexpressing ADRM1 exhibited results that were diametrically opposed to those observed with ADRM1 knockdown. Furthermore, treatment with ICG-001 (a Wnt/β-catenin pathway antagonist) reversed the effects of ADRM1 knockdown in C3H10T1/2 cells.
conclusionsOur findings suggest that silencing ADRM1 induces osteoblast mineralization and differentiation by activating the Wnt/β-catenin pathway. This finding underscores the therapeutic potential of the ADRM1/Wnt/β-catenin axis in treating OP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.